{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T01:36:50Z","timestamp":1775871410720,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Immunology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.humimm.2024.111088","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T18:20:24Z","timestamp":1723659624000},"page":"111088","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Use of Tocilizumab in the treatment of chronic active antibody-mediated rejection in pediatric kidney transplant recipients"],"prefix":"10.1016","volume":"85","author":[{"given":"Maria","family":"Sangermano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2229-1502","authenticated-orcid":false,"given":"Susanna","family":"Negrisolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7011-302X","authenticated-orcid":false,"given":"Benedetta","family":"Antoniello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Vadori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Cozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8939-6376","authenticated-orcid":false,"given":"Elisa","family":"Benetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4 Suppl 1","key":"10.1016\/j.humimm.2024.111088_b0005","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1053\/j.ajkd.2021.01.002","article-title":"US Renal Data System 2020 Annual Data Report: Epidemiology of Kidney Disease in the United States","volume":"77","author":"Johansen","year":"2021","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.humimm.2024.111088_b0010","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","article-title":"Understanding the causes of kidney transplant failure: The dominant role of antibody mediated rejection and non adherence","volume":"12","author":"Sellares","year":"2012","journal-title":"Am J Transplant."},{"issue":"12","key":"10.1016\/j.humimm.2024.111088_b0015","article-title":"Histopathologic Features of Antibody Mediated Rejection: The Banff Classification and Beyond","volume":"27","author":"Cornell","year":"2021","journal-title":"Front Immunol."},{"issue":"4","key":"10.1016\/j.humimm.2024.111088_b0020","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/ajt.14520","article-title":"Treatment of chronic antibody-mediated injury in kidney transplant recipients; a pilot randomized controlled trial","volume":"18","author":"Moreso","year":"2018","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.humimm.2024.111088_b0025","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2326-6066.CIR-14-0022","article-title":"The biology and medical implications of interleukin 6","volume":"2","author":"Tanaka","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"10.1016\/j.humimm.2024.111088_b0030","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1111\/ajt.14228","article-title":"Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients","volume":"17","author":"Choi","year":"2017","journal-title":"Am J Transplant."},{"issue":"8","key":"10.1016\/j.humimm.2024.111088_b0035","doi-asserted-by":"crossref","first-page":"e13908","DOI":"10.1111\/ctr.13908","article-title":"Early effects of first-line treatment with anti-interleukin-6 receptor antibody tocilizumab for chronic active antibody- mediated rejection in kidney transplantation","volume":"34","author":"Lavacca","year":"2020","journal-title":"Clin Transplant."},{"issue":"8","key":"10.1016\/j.humimm.2024.111088_b0040","doi-asserted-by":"crossref","first-page":"e14734","DOI":"10.1111\/ctr.14734","article-title":"Long term Tolerability and Clinical Outcomes associated with Tocilizumab in the Treatment of Refractory Antibody Mediated Rejection (AMR) in Pediatric Renal Transplant Recipients","volume":"36","author":"Pearl","year":"2022","journal-title":"Clin Transplant."},{"issue":"3","key":"10.1016\/j.humimm.2024.111088_b0045","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"10.1016\/j.humimm.2024.111088_b0050","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/ajt.14625","article-title":"The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials","volume":"18","author":"Haas","year":"2018","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.humimm.2024.111088_b0055","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/TP.0b013e3181b11b72","article-title":"HLA-specific antibodies developed in the first year post transplant are predictive of chronic rejection and renal graft loss","volume":"88","author":"Lee","year":"2009","journal-title":"Transplantation."},{"issue":"11","key":"10.1016\/j.humimm.2024.111088_b0060","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/j.1600-6143.2009.02800.x","article-title":"De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure","volume":"9","author":"Hidalgo","year":"2009","journal-title":"Am J Transplant."},{"issue":"5","key":"10.1016\/j.humimm.2024.111088_b0065","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/TP.0000000000003095","article-title":"Recommended Treatment for Antibody-Mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantation Society Working group","volume":"104","author":"Schinstock","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.humimm.2024.111088_b0070","first-page":"1","article-title":"Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: A randomized controlled trial","volume":"00","author":"Chandran","year":"2021","journal-title":"Am J Transplant."},{"key":"10.1016\/j.humimm.2024.111088_b0075","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1111\/ajt.16391","article-title":"Do Anti-IL-6R Blockers Have a Beneficial Effect in the Treatment of Antibody-Mediated Rejection Resistant to Standard Therapy After Kidney Transplantation?","volume":"21","author":"Massat","year":"2021","journal-title":"Am J Transplant."},{"key":"10.1016\/j.humimm.2024.111088_b0080","doi-asserted-by":"crossref","unstructured":"Kumar D, Yakubu I, Safavi F et al. Lack of histology and Molecular Signature Response to Tocilizumab in Kidney Transplant with Chronic Active Antibody Mediated Rejection: A Case Series. Kidney 360. 2020;1(7):663-670. doi: 10.34067\/KID.0000182019.","DOI":"10.34067\/KID.0000182019"}],"container-title":["Human Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885924003483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885924003483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T09:38:03Z","timestamp":1726220283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0198885924003483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0198885924003483"],"URL":"https:\/\/doi.org\/10.1016\/j.humimm.2024.111088","relation":{},"ISSN":["0198-8859"],"issn-type":[{"value":"0198-8859","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of Tocilizumab in the treatment of chronic active antibody-mediated rejection in pediatric kidney transplant recipients","name":"articletitle","label":"Article Title"},{"value":"Human Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humimm.2024.111088","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111088"}}